Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of lanreotide for chemotherapy-induced diarrhoea in colorectal cancer
2014-004473-16Phase 3Terminated
- Sponsor
- Masarykův onkologický ústav
- Start
- Mar 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanreotide in diarrhea and colorectal cancer (CRC), sponsored by Masarykův onkologický ústav. Primary endpoint: Primary efficacy: regression of CID to grade 1. Started Mar 2016; status: terminated.
02
Drugs
lanreotide
03
Conditions
diarrheacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2014-004473-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004473-16.